NCT07226661
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 14 words
- Trial sites expanded: 1 → 40 locations
- Secondary endpoints: details revised at 1 of 1 entry
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jan 1, 2026 to Jan 19, 2026
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Change From Baseline to Day 29 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score.
Timeframe: 4 weeks
Secondary (1)
Change From Baseline to Day 29 in the Clinical Global Impression - Severity of Illness Score (CGI-S).
Arms and interventions
SPN-821 2400 mgExperimental
Three 800 mg oral tablets administered twice a week adjunctive to current antidepressant
PlaceboPlacebo comparator
Three oral tablets administered twice a week adjunctive to current antidepressant
Drugs: SPN-821 2400 mg, Placebo
Sites
40 sites in 1 country